Abstract
In the UK colorectal cancer accounts for 11% of malignant neoplasms in men, and 10% in women. It is the second most common cause of cancer death in men, after carcinoma of the lung, and the third in women, after carcinoma of the breast and lung. Colorectal cancer is the commonest of gastrointestinal cancers and has a median 5 year survival rate of approximately 36%. Although carcinoma of the stomach has a lower incidence (6% in men and 4% in women) it is the fourth most common cause of cancer death in both men and women. It is the second commonest site of gastrointestinal malignancy and has a much poorer prognosis than colorectal cancer with a median five year survival of 11.1% in men and only 9.9% in women (Cancer Research Campaign, 1988-89). The prognosis for both of these conditions is primarily determined by the stage of disease at diagnosis and unfortunately the majority of patients present when the cancer has already invaded the serosal surface of the gut. For this reason it is clear that surgical treatment alone is inadequate.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P, Petcher, T.J. & Pless, J., 1982, SMS201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31, 1133–1140.
Beatson, G.T., 1896, On the treatment of inoperable cases of carcinoma of the mamma. suggestions for a new method of treatment, with illustrated cases. Lancet ii 104–107.
Bogden, A.E., Taylor, J.E., Moreau, J.P., Coy, D.H. & LePage, D.J., 1990, Response of human lung tumour xenografts to treatment with a somatostatin analogue (somatuline). Cancer Res. 50, 4360–4365.
Bradford, M.M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein dye binding. Anal. Biochem. 72, 248–254.
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., Guillemin, R., 1973, Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179, 77–79.
Cai, R.-Z., Szoke, B., Lu, R., Fu, D., Redding, T.W., Schally, A.V., 1986, Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. USA. 83, 1896–1900.
Cancer Research Campaign Factsheets 1.1–9.4, 1988–1990, Cancer Research Campaign, London, UK.
Clements, D. & Elias, E., 1985, Regression of metastatic VIPoma with somatostatin analogue SMS 201–995. Lancet i, 874–875.
Evers, B.M., Parekh, D., Townsend, C.M., Thompson, I.C., 1991, Somatostatin and analogues in the treatment of cancer. Ann. Surg. 213(3), 190–198.
Farmery, S.M., Miller, G.V., Woodhouse, L.F. & Primrose, J.N., 1991, Ionic requirements of [12511iodoTyrll-somatostatin-14 binding sites in human gastric mucosa and rat cerebral cortex. Br. J. Pharmacol. 102(Suppl.), 165P.
Gomez-Pan, A. & Rodriguez-Arnao, M.D., 1983, Somatostatin and growth hormone release factor: synthesis, location, metabolism and function. Clin. Endocrinol. Metab. 12(3), 469–507.
Kraenzlin, M E, Ch’ng, J.L.C., Wood, S.M., Carr, D.H. & Bloom, S.R., 1985, Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.Gastroenterology 88, 185–187.
Lucey M.R., 1986, Endogenous somatostatin and the gut. Gut 27, 457–467.
Miller, G.V., Farmery, S.M., Woodhouse, L.F. & Primrose, J.N., 1992, Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br. J. Cancer (In Press).
Moertel, C.G., Fleming, T.R., Macdonald, J.S., Haller, D.G., Laurie, J.A., Goodman, P.J., Ungerleider, J.S., Emerson, W.A., Tormey, D.C., Glick, J.H., Veeder, M.H. & Mailliard, J.A., 1990, Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322(6), 352–358.
Moreau, J.P. & DeFeudis, F.V., 1987, Pharmacological studies of somatostatin and somatostatinanalogues: therapeutic advances and perspectives. Life Sci. 40, 419–437.
Morris, D.L., Watson, S.A., Harrison, J.D. & Durrant L.G., 1988, Somatostatin (SMS201.995) reduces growth of human gastric cancer (MKN45) xenografts [Abstract]. Gut 29, A1477.
Munson, P.J. & Rodbard, D., 1980, Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107, 220–239.
Murphy, W.A., Lance, V.A., Moreau, S., Moreau, J. -P. & Coy, D.H., 1987, Inhibition of rat prostate tumour growth by an octapeptide analog of somatostatin. Life Sci. 40, 2515–2522.
Patel, Y.C., 1988, Articles on Somatostatin & Analogue Peptides. Investigators’ Newsletter. Current Medical Literature Ltd. London.
Radulovic, S., Miller, G., Schally, A.V., 1991, Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res. 51, 6006–6009.
Redding, T.W. & Schally, A.V., 1984, Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc. Natl. Acad. Sci. USA. 81, 248–252.
Reichlin, S., 1983, Somatostatin (first of two parts). N. Engl. J. Med. 309(24), 1495–1501.
Reichlin, S., 1983, Somatostatin (second of two parts). N. Engl. J. Med. 309(25), 1556–1563.
Reichlin, S., 1987, Secretion of somatostatin and its physiologic function. J. Lab. Clin. Med. 109(3), 320–326.
Reubi, J.C., 1984, Evidence for two somatostatin-14 receptor types in rat brain cortex. Neurosci. Lett. 49, 259–263.
Reubi, J.C. & Maurer, R., 1986, Different ionic requirements for somatostatin receptor subpopulations in the brain., Regul. Pept. 14, 301.-311.
Reubi, J.C., Maurer, R., von Werder, K., Torhorst, J., Klijn, J.G.M. & Lamberts, S.W.J., 1987, Somatostatin receptors in human endocrine tumours. Cancer Res. 47, 551–558.
Reyl-Desmars, F., LeRoux, S., Linard, C., Benkouka, F. & Lewin, M.J.M., 1989, Solubilization and immunopurification of a somatostatin receptor from the human gastric tumoral cell line HGT-1. J. Biol. Chem. 264(31), 18789–18795.
Schally, A.V., Coy, D.H., & Meyers, C.A., 1978, Hypothalamic regulatory hormones. Annu. Rev. Biochem. 47, 89–128.
Schally, A.V. & Redding, T.W., 1987, Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc. Natl. Acad. Sci. USA. 84, 7275–7279.
Schally, A.V., 1988, Oncological applications of somatostatin analogues. Cancer Res,48, 6977–6985.
Smith, J.P. & Solomon, T.E., 1988, Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology 95, 1541–1548.
Srikant, C.B. & Patel, Y.C., 1981, Somatostatin receptors: identification and characterisation in rat brain membranes. Proc. Natl. Acad. Sci. USA. 78, 3930–3934.
Srikant, C.B., Murthy, K.K., Escher, E.E. & Patel, Y.C., 1992, Photoaffinity labelling of the somatostatin receptor: identification of molecular subtypes. Endocrinology 130(5), 2937–2946.
Srkalovic, G., Cai, R.-Z. & Schally, A.V., 1990, Evaluation of receptors for somatostatin in various tumours using different analogs. J. Clin. Endocrinol. Metab. 70(3), 661–669.
Tonnesen, H., Knigge, U., Bulow, S., Damm, P., Fischerman, K., Hesselfeldt, P., Hjortrup, A., Pedersen, I.K., Pedersen, V.M., Siemssen, O.J., Svendsen, L.B. & Christiansen, P.M., 1988, Effect of cimetidine on survival after gastric cancer. Lancet H, 990–992.
Upp Jr., J.R., Olson, D., Poston, G.J., Alexander, R.W., Townsend, C.M. & Thompson, J.C., 1988, Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201–995. Am. J. Surg. 155, 29–35.
Veber, D.F., Holly, F.W., Nutt, R.F., Bergstrand, S.J., Brady, S.F., Hirschmann, R., Glitzer, M.S. & Saperstein, R., 1979, Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature 280, 512–514.
Veber, D.F., Freidinger, R.M., Perlow, D.S., Palevcda Jr., W.J., Holly, F.W., Strachan, R.J., Nutt, R.F., Arison, B.H., Homnick, C., Randall, W.C., Glitzer, M.S., Saperstein, R. & Hirschmann, R., 1981, A potent cyclic hexapeptide analogue of somatostatin. Nature 292, 55–58.
Vinik, A.I., Lloyd, R. & Cho, K., 1990, The use of somatostatin analog in gastroenteropancreatic tumours other than carcinoid. Metabolism 39(9), Supp1.2, 156–162.
Weber, C., Merriam, L., Koschitzky, T., Karp, F., Benson, M., Forde, K. & LoGerfo, P., 1989, Inhibition of growth of human breast carcinomas in vivo by somatostatin analogue, SMS 201–995: treatment of nude mouse xenografts. Surgery 106(2), 416–422.
Wood, S.M., Kraenzlin, M.E., Adrian, T.E. & Bloom, S.R., 1985, Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses. Gut 26, 438–444.
Yamada, Y., Post, S.R., Wang, K., Tager, H.S., Bell, G. & Seino, S., 1992, Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc. Natl. Acad. Sei. USA. 89, 251–255.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Plenum Press, New York
About this chapter
Cite this chapter
Preston, S.R., Miller, G.V., Woodhouse, L.F., Farmery, S.M., Primrose, J.N. (1993). Somatostatin and Human Gastrointestinal Cancer. In: Moody, T.W. (eds) Growth Factors, Peptides and Receptors. GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2846-3_35
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2846-3_35
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-44484-5
Online ISBN: 978-1-4615-2846-3
eBook Packages: Springer Book Archive